Evidence map›Paper›PMID 36387165›Full record

ReviewFrontiers in oncology2022

ALDH1: A potential therapeutic target for cancer stem cells in solid tumors.

Yaolu Wei, Yan Li, Yenan Chen, Pei Liu, Sheng Huang, Yuping Zhang, Yanling Sun, Zhe Wu, Meichun Hu, Qian Wu and 4 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 2 pooled it
9.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 2 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Retinoic acid in health and disease.Signal transduction and targeted therapy · 2026
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. A different perspective on the cancer stem cell theory.Medical oncology (Northwood, London, England) · 2026
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Yaolu WeiSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Yan LiSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Yenan ChenXianning Medical College, Hubei University of Science and Technology, Xianning, China.
Pei LiuXianning Medical College, Hubei University of Science and Technology, Xianning, China.
Sheng HuangXianning Medical College, Hubei University of Science and Technology, Xianning, China.
Yuping ZhangSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Yanling SunSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Zhe WuSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Meichun HuSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Qian WuSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Hongnian WuSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Fuxing LiuSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Tonghui SheSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Zhifeng NingSchool of Basic Medicine Sciences, Xianning Medical College, Hubei University of Science and Technology, Xianning, China.
Hubei University of Science and Technology · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Solid tumors can be divided into benign solid tumors and solid malignant tumors in the academic community, among which malignant solid tumors are called cancers. Cancer is the second leading cause of death in the world, and the global incidence of cancer is increasing yearly New cancer patients in China are always the first. After the concept of stem cells was introduced in the tumor community, the CSC markers represented by ALDH1 have been widely studied due to their strong CSC cell characteristics and potential to be the driving force of tumor metastasis. In the research results in the past five years, it has been found that ALDH1 is highly expressed in various solid cancers such as breast cancer, lung cancer, colorectal cancer, liver cancer, gastric cancer, cervical cancer, esophageal cancer, ovarian cancer, head,and neck cancer. ALDH1 can activate and transform various pathways (such as the USP28/MYC signaling pathway, ALDH1A1/HIF-1α/VEGF axis, wnt/β-catenin signaling pathway), as well as change the intracellular pH value to promote formation and maintenance, resulting in drug resistance in tumors. By targeting and inhibiting ALDH1 in tumor stem cells, it can enhance the sensitivity of drugs and inhibit the proliferation, differentiation, and metastasis of solid tumor stem cells to some extent. This review discusses the relationship and pathway of ALDH1 with various solid tumors. It proposes that ALDH1 may serve as a diagnosis and therapeutic target for CSC, providing new insights and new strategies for reliable tumor treatment.

Indexed as

ALDH1cancer resistancesolid tumorsstem cell markerstargeted therapy

Identifiers

PMID36387165
PMCPMC9650078
OpenAlexW4307702117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.